Mark Moasser, MD, has sorted out why HER2, the protein driving 1 in 5 breast cancers, is so hard to drug. He explains how the findings correct a naive way of envisioning how HER2 is shaped and how it works.

When women's health researchers analyzed Medi-Cal data to see how two long-term contraceptives performed in the real world, they were surprised to find IUDs work at least as well as tubal ligation, while causing fewer side effects.